Important information on minimizing the risk of severe and life-threatening adverse reactions with the use of the medicinal product FLUOROURACILVISTA in patients with partial or complete dihydropyrimidine dehydrogenase deficiency

05.10.2022 1109 views

Важлива інформація з мінімізації ризику розвитку тяжких і загрожуючих життю побічних реакцій при застосуванні лікарського засобу ФЛУОРОУРАЦИЛВІСТА у пацієнтів із частковим або повним дефіцитом дигідропіримідиндегідрогеназиPDF · 697 КБ

Завантажити

Important information on minimizing the risk of severe and life-threatening adverse reactions with the use of the medicinal product FLUOROURACILVISTA in patients with partial or complete dihydropyrimidine dehydrogenase deficiency

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Important information on minimizing the risk of severe and life-threatening adverse reactions with the use of the medicinal product FLUOROURACILVISTA in patients with partial or complete dihydropyrimidine dehydrogenase deficiency

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration